Globus Medical Reports Full Year and Fourth Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Aegis Capital Reiterates Buy on Globus Medical (GMED) Following 4Q EPS Miss
February 28, 2017 7:45 AM ESTAegis Capital reiterated a Buy rating and $31.00 price target on Globus Medical (NYSE: GMED) following the company's 4Q earnings report. Sales grew 6.3% to $151.6 million, driven by Alphatec international sales and recovery in the US market. Non-GAAP EPS of $0.31 was 2 cents short of consensus estimates. Management reiterated FY2017 guidance of $625 million (including a $5 million FX headwind) and non-GAAP EPS of... More
